Vera Therapeutics, Inc. Class A Common Stock (VERA) Stock
NASDAQ · VERA
32.14
Fundamentals
Market cap
$2.34B
Price / Earnings ratio
-6.0x
Price / Sales ratio
N/A
Price / Book ratio
5.9x
Return on assets
-60.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Stocktwits
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
NeutralVERASeptember 16, 2026
StocktwitsNeutral
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
VERA

MarketBeat
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
NeutralVERAJuly 11, 2026
MarketBeatNeutral
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
VERA

Reuters
US FDA approves Vera's kidney disease drug
NeutralVERAJuly 7, 2026
ReutersNeutral
US FDA approves Vera's kidney disease drug
VERA

MarketBeat
3 Biotech Firms With Major Potential Catalysts in the Coming Months
NeutralVERAJune 23, 2026
MarketBeatNeutral
3 Biotech Firms With Major Potential Catalysts in the Coming Months
VERA
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy5
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
882M582M291M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-299.6M
Net incomeEarnings
EPS forecast
Actual EPS
$-1.20
Q1FY26
$-1.18
Q2FY26
The market is expecting earnings per share of -$1.18 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Stocktwits
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
NeutralVERASeptember 16, 2026
StocktwitsNeutral
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
VERA

MarketBeat
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
NeutralVERAJuly 11, 2026
MarketBeatNeutral
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
VERA

Reuters
US FDA approves Vera's kidney disease drug
NeutralVERAJuly 7, 2026
ReutersNeutral
US FDA approves Vera's kidney disease drug
VERA

MarketBeat
3 Biotech Firms With Major Potential Catalysts in the Coming Months
NeutralVERAJune 23, 2026
MarketBeatNeutral
3 Biotech Firms With Major Potential Catalysts in the Coming Months
VERA

MarketBeat
3 Biotech Firms With Major Potential Catalysts in the Coming Months
NeutralVERAJune 21, 2026
MarketBeatNeutral
3 Biotech Firms With Major Potential Catalysts in the Coming Months
VERA

24/7 Wall Street
$20 Billion: Inside Nvidia's VERA CPU Bet to Break the Intel-AMD Duopoly
NeutralVERAJune 4, 2026
24/7 Wall StreetNeutral
$20 Billion: Inside Nvidia's VERA CPU Bet to Break the Intel-AMD Duopoly
VERA

Stocktwits
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment
NeutralVERAJune 2, 2026
StocktwitsNeutral
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment
VERA

24/7 Wall Street
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
NeutralVERAApril 1, 2026
24/7 Wall StreetNeutral
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
VERA

The Motley Fool
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
NeutralVERAMarch 20, 2026
The Motley FoolNeutral
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
VERA

The Motley Fool
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment
NeutralVERAMarch 16, 2026
The Motley FoolNeutral
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment
VERA
About Vera Therapeutics, Inc. Class A Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees361
CEODr. Marshall W. Fordyce M.D.
IPO DateMay 13, 2021
HeadquartersBrisbane, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Marshall W. Fordyce M.D. | Founder, President, CEO & Director | 1975 |
| Mr. Sean P. Grant M.B.A. | Chief Financial Officer | 1985 |
| Mr. David L. Johnson M.B.A. | Chief Opearating Officer | 1970 |
| Dr. Robert M. Brenner M.D. | Chief Medical Officer | 1968 |
| Mr. Joseph R. Young M.B.A. | Senior VP of Finance & Chief Accounting Officer | 1972 |
| Ms. S. Sandra Park J.D. | Senior VP of Legal, Healthcare,Commercial Law, Compliance & Operations | — |
| Dr. Jane Wright-Mitchell J.D., Pharm.D. | Chief Legal Officer & Secretary | 1969 |
| Ms. Debra Charlesworth | Vice President of Corporate Communications | — |
| Ms. Emma Haywood | Vice President of Marketing | — |
| Mr. Tom Doan | Executive Vice President of Development Operations | 1972 |
Fundamentals
Valuation
Market cap$2.34B
Price-to-sales ratioN/A
Price-to-book value5.89
Price-earnings ratio-6.00
Return on Equity-75.00%
Return on SalesN/A
Return on Assets-60.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-5.86
Income Statement
Average volume2,622,896
EBITDA$-359.76M
1 year high (52w)$56.05
1 year low (52w)$23.05
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
6 Wall Street Analyst Ratings
BUY
83% Buy
17% Hold
0% Sell
Target price
$71.83
Est return
120.75%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +5.6 | +6.4 | +102.1 | -19.7 | ||||||||
| 2022 | -29.0 | +15.4 | +2.7 | -12.5 | -27.8 | -2.9 | +30.0 | +27.7 | -0.4 | -8.7 | -8.9 | +18.3 |
| 2023 | -53.7 | -12.5 | +4.9 | -12.0 | +20.1 | +79.3 | +18.1 | -7.3 | -26.1 | -19.5 | +24.0 | +11.1 |
| 2024 | +133.3 | +23.9 | -12.3 | -6.7 | -10.2 | -10.2 | +0.8 | +0.5 | +15.2 | -5.7 | +13.5 | -14.7 |
| 2025 | -11.7 | -18.1 | -15.5 | +6.1 | -20.2 | -25.8 | -9.6 | +3.3 | +28.5 | -1.1 | +30.1 | +53.5 |
| 2026 | -11.0 | -9.9 | -0.5 | -12.1 | +0.9 | +26.4 | -24.8 | +5.7 | -4.9 |



